for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Astellas Pharma Inc

4503.T

Latest Trade

1,826.00JPY

Change

20.50(+1.14%)

Volume

2,499,700

Today's Range

1,813.50

 - 

1,827.50

52 Week Range

1,356.00

 - 

1,894.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Astellas Pharma To Buy Back And Cancel Treasury Stock

Oct 31 (Reuters) - Astellas Pharma Inc <4503.T>::ANNOUNCES ACQUISITION OF OWN SHARES AND CANCELLATION OF TREASURY STOCK.TO BUY BACK UP TO 1.7% OF SHARES WORTH 50 BILLION YEN THROUGH JAN 31 AND THEN CANCEL ALL OF THEM.

EU Medicines Agency Says CHMP Recommends Granting Marketing Authorisation For AstraZeneca's Drug Qtrilmet

Sept 20 (Reuters) - SailPoint Technologies Holdings Inc <SAIL.N>::SAILPOINT ANNOUNCES PRICING OF UPSIZED $350 MILLION CONVERTIBLE SENIOR NOTES OFFERING.SAILPOINT TECHNOLOGIES - ANNOUNCED PRICING OF $350 MILLION AGGREGATE PRINCIPAL AMOUNT OF 0.125% CONVERTIBLE SENIOR NOTES DUE 2024.SAILPOINT TECHNOLOGIES HOLDINGS INC - AGGREGATE PRINCIPAL AMOUNT OF OFFERING WAS INCREASED FROM OFFERING SIZE OF $300 MILLION.SAILPOINT TECHNOLOGIES- GRANTED INITIAL PURCHASERS OF NOTES 13-DAY OPTION TO PURCHASE UP TO ADDITIONAL $50 MILLION AGGREGATE PRINCIPAL AMOUNT OF NOTES.SAILPOINT TECHNOLOGIES HOLDINGS INC - INTENDS TO USE A PORTION OF NET PROCEEDS OF OFFERING TO PAY COST OF CAPPED CALL TRANSACTIONS.

Fibrogen Says Evrenzo Approved By Japan’s Ministry of Health, Labour and Welfare

Sept 20 (Reuters) - Fibrogen Inc::FIBROGEN-JAPAN'S MINISTRY OF HEALTH,LABOUR AND WELFARE APPROVED EVRENZO FOR TREATMENT OF ANEMIA RELATED TO CHRONIC KIDNEY DISEASE IN DIALYSIS PATIENTS.

Astellas Pharma Says Japan's Ministry Of Health, Labour And Welfare Approved Evrenzo(Roxadustat)

Sept 20 (Reuters) - Astellas Pharma Inc <4503.T>::EVRENZO® (ROXADUSTAT) TABLETS APPROVED IN JAPAN FOR TREATMENT OF ANEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE IN DIALYSIS PATIENTS.JAPAN'S MINISTRY OF HEALTH, LABOUR AND WELFARE APPROVED EVRENZO.APPROVAL IS BASED ON FOUR PHASE 3 STUDIES CONDUCTED IN CKD ANEMIA PATIENTS ON DIALYSIS IN JAPAN.PHASE 3 STUDIES DEMONSTRATED THAT ROXADUSTAT WAS EFFECTIVE AT RAISING HEMOGLOBIN AND THAT IT WAS WELL-TOLERATED.

Seattle Genetics And Astellas Announce U.S. FDA Grants Priority Review For Enfortumab Vedotin Biologics License Application In Locally Advanced Or Metastatic Urothelial Cancer

Sept 16 (Reuters) - Seattle Genetics Inc <SGEN.O>::SEATTLE GENETICS AND ASTELLAS ANNOUNCE U.S. FDA GRANTS PRIORITY REVIEW FOR ENFORTUMAB VEDOTIN BIOLOGICS LICENSE APPLICATION IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER.SEATTLE GENETICS INC - FOOD & DRUG ADMINISTRATION SETS PRESCRIPTION DRUG USER FEE ACTION DATE FOR MARCH 15, 2020.

U.S. FDA Grants Xtandi Application Priority Review For Treatment Of Men With Metastatic Hormone-Sensitive Prostate Cancer

Aug 21 (Reuters) - Astellas Pharma Inc <4503.T>::U.S. FDA GRANTS XTANDI® (ENZALUTAMIDE) APPLICATION PRIORITY REVIEW FOR THE TREATMENT OF MEN WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER.ASTELLAS PHARMA INC - FDA HAS SET A PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE, OR TARGET ACTION DATE, IN Q4 2019.ASTELLAS PHARMA - U.S. FDA GRANTS XTANDI APPLICATION PRIORITY REVIEW FOR TREATMENT OF MEN WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER.

Ironwood Pharmaceuticals To No Longer Be Responsible For Supply Of Linaclotide API To Astellas

Aug 1 (Reuters) - Astellas Pharma Inc <4503.T>::IRONWOOD PHARMACEUTICALS INC - BEGINNING ON JANUARY 1, 2020, CO WILL NO LONGER BE RESPONSIBLE FOR SUPPLY OF LINACLOTIDE API TO ASTELLAS.IRONWOOD PHARMACEUTICALS INC - BEGINNING JAN 1, 2020 ASTELLAS WILL BE RESPONSIBLE FOR ITS OWN SUPPLY OF LINACLOTIDE API FOR SALE IN JAPAN.IRONWOOD PHARMACEUTICALS INC - ASTELLAS HAS COMMITTED TO PURCHASE CERTAIN QUANTITIES OF LINACLOTIDE API FROM CO IN CALENDAR YEAR 2019.IRONWOOD PHARMACEUTICALS INC - IN CONSIDERATION FOR FOREGOING RIGHTS, ASTELLAS WILL PAY IRONWOOD A NON-REFUNDABLE UPFRONT PAYMENT OF $10 MILLION.IRONWOOD - BEGINNING JAN 1, 2020, ASTELLAS TO PAY ROYALTIES TO CO AT RATES BEGINNING IN MID-SINGLE DIGIT PERCENT IN LIEU OF ROYALTY PAYMENT TERMS.IRONWOOD PHARMACEUTICALS INC - ROYALTY PAYMENTS WILL NOT BE DUE ON NET SALES OF PRODUCTS IN CALENDAR YEAR 2019.IRONWOOD - AS RESULT OF EXECUTION OF AMENDED AND RESTATED AGREEMENT, CO NOW EXPECTS TOTAL 2019 REVENUE FROM ASTELLAS TO BE APPROXIMATELY $55 MILLION.

Astellas And Frequency Therapeutics Enter Into License Agreement For FX-322

July 17 (Reuters) - Astellas Pharma Inc <4503.T>::ASTELLAS AND FREQUENCY THERAPEUTICS ENTER INTO LICENSE AGREEMENT FOR FX-322, A REGENERATIVE TREATMENT CANDIDATE FOR HEARING LOSS.ASTELLAS PHARMA - ASTELLAS WILL BE RESPONSIBLE FOR DEVELOPMENT AND COMMERCIALIZATION OF FX-322 OUTSIDE OF THE U.S..ASTELLAS PHARMA - AS PER LICENSE AGREEMENT, FREQUENCY WILL RECEIVE AN UPFRONT PAYMENT OF $80 MILLION.ASTELLAS PHARMA - AS PER LICENSE AGREEMENT, FREQUENCY MAY ALSO GET UP TO ADDITIONAL $545 MILLION BASED ON DEVELOPMENT & COMMERCIAL MILESTONES, ROYALTIES.ASTELLAS PHARMA - FREQUENCY WILL BE RESPONSIBLE FOR U.S. DEVELOPMENT AND COMMERCIALIZATION FOR FX-322.ASTELLAS PHARMA - FREQUENCY PLANS TO INITIATE PHASE 2A STUDY IN Q4 2019 FOR FX-322.ASTELLAS PHARMA - REFLECTED IMPACT FROM LICENSE AGREEMENT FOR FX-322 IN ITS FINANCIAL FORECASTS OF CURRENT FISCAL YEAR ENDING MARCH 31, 2020.

Astellas And Seattle Genetics Announce Submission Of Biologics License Application To FDA

July 16 (Reuters) - Seattle Genetics Inc <SGEN.O>::ASTELLAS AND SEATTLE GENETICS ANNOUNCE SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO FDA FOR ENFORTUMAB VEDOTIN FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER.

Seattle Genetics And Astellas Announce Submission Of Biologics License Application To FDA

July 16 (Reuters) - Seattle Genetics Inc <SGEN.O>::SEATTLE GENETICS AND ASTELLAS ANNOUNCE SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO FDA FOR ENFORTUMAB VEDOTIN FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up